Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
11.23
-0.50 (-4.26%)
At close: Nov 10, 2026, 4:00 PM EST
11.23
0.00 (0.00%)
Pre-market: Nov 11, 2026, 7:49 AM EST
Cullinan Therapeutics Stock Forecast
Stock Price Forecast
According to 12 analysts polled by S&P Global, Cullinan Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $34.7. The average 1-year stock price forecast is 208.99% higher than the current stock price, while the lowest is $27 (+140.43%) and the highest is $44 (+291.81%).
Price Target: $34.7 (+208.99%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Cullinan Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 11 | 11 | 11 | 11 | 11 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JonesTrading | JonesTrading | Buy Maintains $36 | Buy | Maintains | $36 | +220.57% | Nov 10, 2026 |
| UBS | UBS | Buy Maintains $27 | Buy | Maintains | $27 | +140.43% | Nov 10, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains $28 | Buy | Maintains | $28 | +149.33% | Nov 9, 2026 |
| Wedbush | Wedbush | Buy Reiterates $42 | Buy | Reiterates | $42 | +274.00% | Nov 9, 2026 |
| BTIG | BTIG | Buy Maintains $41 | Buy | Maintains | $41 | +265.09% | Nov 9, 2026 |
Financial Forecast
Revenue This Year
15.42M
Revenue Next Year
65.96M
from 15.42M
Increased by 327.77%
EPS This Year
-3.10
from -3.36
EPS Next Year
-2.42
from -3.10
EPS and Forward PE are based on non-GAAP adjusted numbers.